المؤلفون: Vladimir Vasilyev Ivanovich, V Gorodetsky R, S Sedyshev Kh, O Logvinenko A, N Probatova A, A Pavlovskaya I, M Eliseyev S, A Smirnov V, G Fadienko R, В. Васильев И., В. Городецкий Р., С. Седышев Х., О. Логвиненко А., Н. Пробатова А., А. Павловская И., А. Смирнов В.

المصدر: Rheumatology Science and Practice; Vol 51, No 2 (2013); 205-209 ; Научно-практическая ревматология; Vol 51, No 2 (2013); 205-209 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-2

العلاقة: Демидова А.В., Хорошко Н.Д. Сублейкемический миелоз. В кн.: Руководство по гематологии. Под ред. академика А.И. Воробьева. М.: Ньюдиамед, 2003;2:16-20 Spivak J.L. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004;41(Suppl 3):1-5. Baxter E.J., Scott L.M., Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61. Heinicke M.H., Zarrabi M.H., Gorevic P.D. Arthritis due to synovial involvement by extramedullary haemotopoiesis in myelofibrosis with myeloid metaplasia. Ann Rheum Dis 1983;42:196-200. McCarty D.M. Fibrosis of the bone marrow: content and causes. Br J Haemat 1985;59:1-7. Lichtman M.A. Primary myelofibrosis. Ch.91. Williams Hematology. 8th еd. Eds Kaushansky K., Lichtman M.A., Beuter E., Kipps T.J., Seligsohn V., Prchal J.T. McGraw-Hill Companies, 2010. Marie I., Levesque H., Cailleux N. et al. An uncommon association: Sjogren’s syndrome and autoimmune myelofibrosis. Rheumatology 1999;38:370. Васильев В.И., Симонова М.В., Сафонова Т.Н. Критерии диагноза болезни и синдрома Шегрена. В кн.: Избранные лекции по клинической ревматологии. Под ред. В.А. Насоновой, Н.В. Бунчука. М.: Медицина, 2001;112—31. Altman A. Acute tumor lysis syndrome. Sem Oncol 2001;28(Suppl):3-8. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm 2006;63:1172-93. Arnold T.M., Reuter J.P., Delman B.S., Shanholtz C. Use of single-dose Rasburicase in an obese female. Ann Pharmacoter 2004;38:1428-31. Насонов Е.Л., Александрова Е.Н. Применение Ритуксимаба при ревматоидном артрите. Науч-практич ревматол 2010;4(Прил. 1):10-40. Spivak J.L. Polycythemia vera and other myeloproliferative disease. 17th ed. Harrison’s Principles of International Medicine. Eds Fauci A.S., Braunwald E., Kasper D.L., Hauser S.L., Longo D.L., Jameson J.L., Loscalzo J. Mеdical Mc Graw-Hill, 2008:671-3. Jacobson R.I., Salo A., Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoetic stem cells with secondary myelofibrosis. Blood 1978;51:189-94. Логвиненко О.А., Васильев В.И. Неходжкинские лимфомы при ревматических заболеваниях. Науч-практич ревматол 2011;5:71-83. Васильев В.И., Пробатова Н.А., Тупицын Н.Н. и др. Лимфопролиферативные заболевания при болезни Шегрена. Онкогематология 2007;3:16-26. Васильев В.И. Болезнь Шегрена: клинико-лабораторные, иммуноморфологические проявления и прогноз: Автореф. дис. д-ра мед. наук. М., 2007:1-46. Exposito R.S., Moreno R.J., Reolid C.E. et al. Idiopathic myelofibrosis associated with rheumatoid arthritis. Med Clin (Barc) 1994;102:277. Jain V., Baheshwari A., Gulati S. et al. Juvenile rheumatoid arthritis with myelofibrosis with myeloid metaplasia. Ind J Ped 2005;72:789-91. Ong A., Quach H., Lech M. et al. Reversal of of transfusion depence by TNF-inhibitor treatment a patient with concurrent Ra and primary myelofibrosis. J Clin Rheum 2011;17:211-3. Pavithram K., Thomas M. Chronic myeloid leukemia presenting as gout. Clin Rheumatol 2001;20:288-9. Teferri A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms. The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.; https://rsp.mediar-press.net/rsp/article/view/788Test

الإتاحة: https://doi.org/10.14412/1995-4484-2013-650Test
https://doi.org/10.14412/1995-4484-2013-2Test
https://rsp.mediar-press.net/rsp/article/view/788Test

المؤلفون: Samir Sedyshev Khasanovich, V Vasiliev I, A Kovriguina M, E Nasonov L, С. Седышев Х., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 50, No 5 (2012); 64-72 ; Научно-практическая ревматология; Vol 50, No 5 (2012); 64-72 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-5

وصف الملف: application/pdf

العلاقة: https://rsp.mediar-press.net/rsp/article/view/1098/771Test; Zhang L., Smyrk T.C. Autoimmune pancreatitis and IgG4-related systemic diseases. Int J Clin Exp Pathol 2010; 3: 491-504. Aucouturier A., Danon F., Daveau M. et al. Measurement of serum IgG4 levels by a competitive immunoenzymatic assay with monoclonal antibodies. J Immun Meth 1984; 74: 151-62. Meulenbroek A.J., Zeijlemaker W.P. Human IgG Subclasses: useful diagnostic markers for immunocompetence [online]. Sanquin, Laboratory for Experimental and Clinical Immunology University of Amsterdam, the Netherlands; 1996 (http://www.xs4all.nl/_ednieuw/IgGsubclasses/subkl.htmTest). Salfeld J.G. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25: 1369-72. Aalberse R.C., Stapel S.O., Schuurman J. et al. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-77. Zen Y., Fujii T., Harada K. et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007; 45(6): 1538-46. Aalberse R.C., Platts-Mills T.A. How do we avoid developing allergy: modifications of the TH2 response from a B-cell perspective. J Allergy Clin Immunol 2004; 113: 983-6. Kawa S., Ota M., Yoshizawa K. et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 2002; 122: 1264-9. Scalapino K.J., Daikh D.I. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev 2008; 223: 143-55. Chang M.C., Chang Y.T., Tien Y.W. et al. T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clin Chem 2007; 53: 1700-5. Umemura T., Ota M., Hamano H. et al. Association of autoimmune pancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. Am J Gastroenterol 2008; 103: 588-94. Okazaki K., Uchida K., Ohana M. et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology 2000; 118: 573-81. Aparisi L., Farre A., Gomez-Cambronero L. et al. Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis. Gut 2005; 54: 703-9. Nishimori I., Miyaji E., Morimoto K. et al. Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis. Gut 2005; 54: 274-81. Asada M., Nishio A., Uchida K. et al. Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis. Pancreas 2006; 33: 20-6. Löhr J.M., Faissner R., Koczan D. et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am J Gastroenterol 2010; 105: 2060-71. Yamamoto M., Naishiro Y., Suzuki C. et al. Proteomics analysis in 28 patients with systemic IgG4-related plasmacytic syndrome. Rheumatol Int 2010; 30: 565-8. Akitake R., Watanabe T., Zaima C. et al. Possible involvement of T helper type 2 responses to Toll-like receptor ligands in IgG4-related sclerosing disease. Gut 2010; 59: 542-5. Miyake K., Moriyama M., Aizawa K. et al. Peripheral CD4 T cells showing aTh2 phenotype in a patient with Mikulicz's disease associated with lymphadenopathy and pleural effusion. Mod Rheumatol 2008; 18: 86-90. Kudo-Tanaka E., Nakatsuka S., Hirano T. et al. A case of Mikulicz's disease with Th2-biased cytokine profile: possible feature discriminable from Sjö gren's syndrome. Mod Rheumatol 2009; 19: 691-5. Suzuki K., Tamaru J.I., Okuyama A. et al. IgG4-positive multiorgan lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked il 4 elevation. Rheumatology (Oxford) 2010; 49: 1789-91. Kanari H., Kagami S., Kashiwakuma D. et al. Role of Th2 cells in IgG4-related lacrimal gland enlargement. Int Arch Allergy Immunol 2010; 152(Suppl. 1): 47-53. Zen Y., Fujii T., Harada K et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007; 45(6): 1538—46. Koyabu M., Uchida K., Miyoshi H. et al. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J Gastroenterol 2010; 45: 732-41. Miyoshi H., Uchida K., Taniguchi T. et al. Circulating naive and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas 2008; 36: 133-40. Detlefsen S., Sipos B., Zhao J. et al. Autoimmune pancreatitis: expression and cellular source of profibrotic cytokines and their receptors. Am J Surg Pathol 2008; 32: 986-95. Kamisawa T., Anjiki H., Egawa N., Kubota N. Allergic manifestations in autoimmune pancreatitis. Eur J Gastroenterol Hepatol 2009; 21: 1136-9. Sah R.P., Pannala R., Zhang L. et al. Eosinophilia and allergic disorders in autoimmune pancreatitis. Am J Gastroenterol 2010. doi:10.1038/ ajg.2010.236 [Epub. ahead of print]. Kojima M., Sipos B., Klapper W. et al. Autoimmune pancreatitis: frequency, IgG4 expression, and clonality of T and B cells. Am J Surg Pathol 2007; 31: 521-8. Song M.H., Kim M.H., Jang S.J. et al. Comparison of histology and extracellular matrix between autoimmune and alcoholic chronic pancreatitis. Pancreas 2005; 30: 272-8. Suda K., Nishimori I., Takase M. et al. Autoimmune pancreatitis can be classified into early and advanced stages. Pancreas 2006; 33: 345-50. Dhall D., Suriawinata A.A., Tang L.H. et al. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. Human Pathol 2010; 41: 643-52. Geyer J.T., Deshpande V. IgG4-associated sialadenitis. Curr Opin Rheumatol 2011; 23: 95-101. Smyrk T.C. Pathological features of IgG4-related sclerosing disease. Curr Opin Rheumatol 2011; 23(1): 74-9 Masaki Y., Dong L., Kurose N. et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 1310-5. Yoshida K., Toki F., Takeuchi T. et al. Chronic pancreatitis caused by an autoimmune abnormality: proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995; 40: 1561-8. Montano-Loza A.J., Lalor E., Mason A.L. Recognizing immunoglobulin G4-related overlap syndromes in patients with pancreatic and hepatobiliary diseases. Can J Gastroenterol 2008; 22(10): 840-6. Chari S.T., Kloeppel G., Zhang L. et al. Histopathologic and clinical subtypes ofautoimmune pancreatitis: the Honolulu consensus document. Pancreas 2010; 39: 549-54. Okazaki K., Kawa S., Kamisawa T. et al. Japanese clinical guidelines for autoimmune pancreatitis. Pancreas 2009; 38: 849-66. Kamisawa T., Egawa N., Nakajima H. et al. Extrapancreatic lesions in autoimmune pancreatitis. J Clin Gastroenterol 2005; 39: 904-7. Kamisawa T., Funata N., Hayashi Y. et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38: 982-4. Kamisawa T., Nakajima H., Egawa N. et al. IgG4-related sclerosing disease incorporating sclerosing pancreatitis, cholangitis, sialadenitis and retroperitoneal fibrosis with lymphadenopathy. Pancreatology 2006; 6: 132-7. Kamisawa T., Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 2006; 41: 613—25. Okazaki K., Kawa S., Kamisawa T. et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol 2006; 41: 626—31 Zamboni G., Luttges J., Capelli P. et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virch Arch 2004; 445: 552-63. Park D.H., Kim M.H., Chari S.T. Recent advances in autoimmune pancreatitis. Gut 2009; 58: 1680-9. Kamisawa T., Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol 2008; 14: 3948-55. Chari S.T., Takahashi N., Levy M.J. et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 10: 1097-103. Okazaki K., Kawa S., Kamisawa T. et al. Japanese consensus guidelines for management of autoimmune pancreatitis. I: Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol 2010; 45: 249-65. Kamisawa T., Takuma K., Egawa N. et al. Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol 2010; 4: 401—9. Raina A., Krasinskas A.M., Greer J.B. et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008; 132: 48-53. Ghazale A., Chari S.T., Smyrk T.C. et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102: 1646—53. Kamisawa T., Shimosegawa T., Okazaki K. et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504—7. LaRusso N.F., Wiesner R.H., Ludwig J. et al. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984; 310: 899—903. Wiesner R.H., Grambsch P.M., Dickson E.R. et al. Primary sclerosing cholangitis: natural history, prognostic factor and survival analysis. Hepatology 1989; 10: 430-6. Kamisawa T., Takuma K., Anjiki H. et al. Sclerosing cholangitis associated with autoimmune pancreatitis differs from primary sclerosing cholangitis. World J Gastroenterol 2009; 15: 2357—60. Hamano H., Kawa S., Uehara T. et al. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? Gastrointest Endosc 2005; 62: 152—7. Hayashi K., Nakazawa T., Ohara H. et al. Autoimmune sclerosing cholangiopancreatitis with little pancreatic involvements by imaging findings. Hepatogastroenterology 2007; 54: 2146-51. Nishino T., Oyama H., Hashimoto E. et al. Clinicopathological differences between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J Gastroenterol 2007; 42: 550—9. Alderlieste Y.A., Elzen B.D.J., Rauws E.A.J. et al. Immunoglobulin G4-associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion 2009; 79: 220—8. Bjornsson E., Chari S., Sliveira M. et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther (in press). Mikulicz J. Uber eine eigenartige symmetrische erkrankung der thrä nen- und mundspeicheldrü sen. In: Billroth T., ed. Beiträ ge zur chirurgie festschrift gewidmet. Stuttgart: Ferdinand Enke, 1892; 610—30. Cимонова М.В., Васильев В.И., Корнилова Н.Н. и др. Дифференциальная диагностика болезни Микулича и болезни Шегрена. Стоматология 1988; 3: 71-3. Mikulicz J. Concerning a peculiar symmetrical disease of the lacrimal and salivary glands. Modern Classics 1937—1938; 2: 165—86. Morgan W. S., Castleman B. A clinicopathologic study of Mikulicz's disease.Am J Pathol 1953; 29: 471-503. Васильев В.И., Пальшина С.Г., Симонова М.В. и др. Первый опыт использования ритуксимаба в терапии болезни Микулича. Тер. арх. 2010; 6: 62-6. Sjögren H. Zur Kenntnis der Keratoconjunctivitis Sicca (Keratitis filiformis bei Hypofunktion der Tranendrusen). Acta Ophthalmol 1933(Suppl. II): 1—151. Morgan W.S. The probable systemic nature of Mikulicz's disease and its relation to Sjogren's syndrome. N Engl J Med 1954; 251: 5—10. MacLean H., Ironside J.W., Cullen J.F., Butt Z. Mikulicz syndrome and disease: 2 case reports high-lighting the difference. Acta Ophthalmol (Copenh) 1993; 71: 136-41. Yamamoto M., Harada S., Ohara M. et al. Clinical and pathological differences between Mikulicz's disease and Sjogren's syndrome. Rheumatology (Oxford) 2005; 44: 227-34. Yamamoto M., Takahashi H., Ohara M. et al. A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod Rheumatol 2006; 16: 335-40 Kubota K., Wada T., Kato S. et al. Highly active state of autoimmune pancreatitis with Mikulicz's disease. Pancreas 2010; 39: e6—e10. Kü ttner H. Uber entzundiche tumoren der submaaxillar-speicheldruse. Beitr Klin Chir 1896; 15: 815-34. Chan J.K. Kuttner tumor (chronic sclerosing sialadenitis) of the submandibular gland: an underrecognized entity. Adv Anat Pathol 1998; 5: 239—51. Chow T.L., Chan T.T., Choi C.Y., Lam S.H. Kuttner's tumour (chronic sclerosing sialadenitis) of the submandibular gland: a clinical perspective. Hong Kong Med J 2008; 14: 46-9. Harrison J.D., Epivatianos A., Bhatia S.N. Role of microliths in the aetiology of chronic submandibular sialadenitis: a clinicopathological investigation of 154 cases. Histopathology 1997; 31: 237—51. Rasanen O., Jokinen K., Dammert K. Sclerosing inflammation of the submandibular salivary gland (Kuttner tumour): a progressive plasmacellular ductitis. Acta Otolaryngol 1972; 74: 297—301. Isacsson G., Isberg A., Haverling M., Lundquist P.G. Salivary calculi and chronic sialoadenitis of the submandibular gland: a radiographic and histologic study. Oral Surg Oral Med Oral Pathol 1984; 58: 622-7. Tiemann M., Teymoortash A., Schrader C. et al. Chronic sclerosing sialadenitis of the submandibular gland is mainly due to a T lymphocyte immune reaction. Mod Pathol 2002; 15: 845—52. Kamisawa T., Nakajima H., Hishima T. Close correlation between chronic sclerosing sialadenitis and immunoglobulin G4. Intern Med J 2006; 36: 527-9. Takano K.I., Yamamoto M., Takahashi H. et al. Clinicopathologic similarities between Mikulicz disease and Kü ttner tumor. Am J Otolaryngol 2009 Oct 30 [Epub. ahead of print]. Jacobs D., Galetta S. Diagnosis and management of orbital pseudotumour. Curr Opin Ophthalmol 2002; 13: 347-51. Mombaerts I., Goldschmeding R., Schlingemann R.O., Koornneef L. What is orbital pseudotumour? Surv Ophthalmol 1996; 41: 66—78. Rootman J., Nugent R. The classification and management of acute orbital pseudotumours. Ophthalmology 1982; 89: 1040-8. Shikishima K., Kawai K., Kitahara K. Pathological evaluation of orbital tumours in Japan: analysis of a large case series and 1379 cases reported in the Japanese literature. Clin Exp Ophthalmol 2006; 34: 239-44. Yuen S.J.A., Rubin P.A.D. Idiopathic orbital inflammation: ocular mechanisms and clinicopathology. Ophthalmol Clin North Am 2002; 15: 121-6. Leone C.R. Jr, Lloyd W.C. 3rd. Treatment protocol for orbital inflammatory disease. Ophthalmology 1985; 92: 1325-31. Orcutt J.C., Garner A., Henk J.M. et al. Treatment of idiopathic inflammatory orbital pseudotumours by radiotherapy. Br J Ophthalmol 1983; 67: 570-4. Rootman J., McCarthy M., White V. et al. Idiopathic sclerosing inflammation of the orbit. A distinct clinicopathologic entity. Ophthalmology 1994; 101: 570-84. Abramovitz J.N., Kasdon D.L., Sutula F. et al. Sclerosing orbital pseudotumour. Neurosurgery 1983; 12: 463-8. Weissler M.C, Miller E., Fortune M.A. Sclerosing orbital pseudotumour: a unique clinicopathologic entity. Ann Otol Rhinol Laryngol 1989; 98: 496-501. McCarthy J.M., White V.A., Harris G. et al. Idiopathic sclerosing inflammation of the orbit: immunohistologic analysis and comparison with retroperitoneal fibrosis. Mod Pathol 1993; 6: 581-7. Swamy B.N., McCluskey P., Nemet A. Idiopathic orbital inflammatory syndrome: Clinical features and treatment outcomes. Br J Ophthalmol 2007; 91(12): 1667-70. Kamisawa T., Yoshiike M., Egawa N. et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology 2005; 5: 234-8. Chari S.T., Smyrk T.C., Levy M.J. et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 2006; 4: 1010-6. Wakabayashi T., Kawaura Y., Satomura Y. et al. Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. Pancreas 2005; 30: 31-9. Kubota K., Iida H., Fujisawa T. et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc 2007; 66: 1142-51. Park D.H., Kim M.H., Chari S.T. Recent advances in autoimmune pancreatitis. Gut 2009; 58: 1680-9. Kamisawa T., Chung J.B., Irie H. et al. Japan-Korea Symposium on Autoimmune Pancreatitis (KOKURA 2007). Pancreas 2007; 35: 281-4. Ito T., Nishimori I., Inoue N. et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol 2007; 42(Suppl. 18): 50-8. Ko S.B., Mizuno N., Yatabe Y. et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology 2010; 138: 1988-96. Kamisawa T., Shimosegawa T., Okazaki K. et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-7. Kamisawa T., Okazaki K., Kawa S. et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010; 45: 471-7. Kim H.M., Chung M.J., Chung J.B. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas 2010; 39: 555-60. Pannala R., Chari S.T. Corticosteroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1438-9. Hirano K., Tada M., Isayama H. et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56: 1719-24. Church N.I., Pereira S.P., Deheragoda M.G. et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol 2007; 102: 2417-25. Khosroshahi A., Bloch D.B., Deshpande V., Stone J.H. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthr Rheum 2010; 62: 1755-62. Pennisi A., Li X., Ling W. et al. The proteasome inhibitor, borte-zomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009; 84: 6-14. Khan M.L., Colby T.V., Viggiano R.W., Fonseca R. Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk 2010; 10: 217-9.; https://rsp.mediar-press.net/rsp/article/view/1098Test

الإتاحة: https://doi.org/10.14412/1995-4484-2012-1184Test
https://doi.org/10.14412/1995-4484-2012-5Test
https://rsp.mediar-press.net/rsp/article/view/1098Test

المؤلفون: Vadim Gorodetsky Romanovich, V Vasilyev I, S Sedyshev Kh, M Ogorodnikova D, L Bozhyeva A, E Nasonov L, В. Городецкий Р., В. Васильев И., С. Седышев Х., Л. Божьева А., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 50, No 2 (2012); 76-80 ; Научно-практическая ревматология; Vol 50, No 2 (2012); 76-80 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-2

وصف الملف: application/pdf

العلاقة: https://rsp.mediar-press.net/rsp/article/view/1171/843Test; Wegener F. On generalised septic vessel diseases. Thorax 1987;42:918-9. Godman G.C., Churg J. Wegener's granulomatosis: pathology and review of the literature. AMA Arch Path 1954;58:533-53. Leavitt R.Y., Fauci A.S., Bloch D.A. et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthr Rheum 1990;33:1101-7. Jennette J.C., Falk R.J., Andrassy K. et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthr Rheum 1994;37:187-92. Hoffman G.S., Kerr G.S., Leavitt R.Y. et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98. Reinhold-Keller E., Beuge N., Latza U. et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthr Rheum 2000;43:1021-32. Yi E.S., Colby T.V. Wegener Granulomatosis. Semin Diagn Pathology 2001;18:34-46. Bosch X., Guilabert A., Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006;368:404-18. Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxford) 2002;41:481-3. Hewins P., Tervaert J.W., Savage C.O. et al. Is Wegener's granulomatosis an autoimmune disease? Curr Opin Rheumatol 2000;12:3-10. Hellmich B., Flossmann O., Gross W.L. et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17. Hunder G.G., Arend W.P., Bloch D.A. et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: Introduction. Arthr Rheum 1990;33:1065-7. Bloch D.A., Michel B.A., Hunder G.G. et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: patients and methods. Arthr Rheum 1990;33:1068-73. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001;13:48-55. Schmitt W.H., Hagen E.C., Neumann I. et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004;65:1440-8. Langford C.A., Hoffman G.S. Wegener's granulomatosis. Thorax 2000;54:629-37. Novack S.N., Pearson C.M. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 1971;284:938-42. Fauci A.S., Wolff S.M. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973;52:535-61. Hoffman G.S., Kerr G.S., Leavitt R.Y. et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98. Reinhold-Keller E., Beuge N., Latza U. et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthr Rheum 2000;43:1021-32. Stone J.H., Merkel P.A., Spiera R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32. Jones R.B., Tervaert J.W., Hauser T. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20. de Groot K., Harper L., Jayne D.R. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80. Jayne D.R., Gaskin G., Rasmussen N. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8. de Groot K., Rasmussen N., Bacon P.A. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthr Rheum 2005;52:2461-9. Rutgers A., Kallenberg C.G.M. Refractory vasculitis. Autoimmun Rev 2011;10:702-6. Ramos-Casals M., Garcia-Hernandez F.J., de Ramon E. et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010;28:468-76. Jones R.B., Ferraro A.J., Chaudhry A.N. et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthr Rheum 2009;60:2156-68. Roccatello D., Baldovino S., Alpa M. et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008;26:S67-S71. Seo P., Specks U., Keogh K.A. Efficacy of rituximab in limited Wegeners granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008;35:2017-23. Smith K.G., Jones R.B., Burns S.M., Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthr Rheum 2006;54:2970-82. Stasi R., Stipa E., Del Poeta G. et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006;45:1432-6. Keogh K.A., Ytterberg S.R., Fervenza F.C. et al. Rituximab for refractory Wegeners granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7. Walsh M., Chaudhry A., Jayne D. Long-term follow-up of relapsing/refractory antineutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1 H). Ann Rheum Dis 2008;67:1322-7. Benenson E., Fries J.W., Heilig B. et al. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegeners granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol 2005;24:251-7. Bartolucci P., Ramanoelina J., Cohen P. et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002;41:1126-32. Booth A., Harper L., Hammad T. et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibodyassociated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21. Birck R., Warnatz K., Lorenz H.M. et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-7. Flossmann O., Baslund B., Bruchfeld A. et al. Deoxyspergualin in relapsing and refractory Wegeners granulomatosis. Ann Rheum Dis 2009;68:1125-30. Stassen P.M., Tervaert J.W., Stegeman C.A. Induction of remission in active antineutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007;66:798-802. Statkute L., Oyama Y., Barr W.G. et al. Autologous nonmyeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis. Ann Rheum Dis 2008;67:991-7. Kotter I., Daikeler T., Amberger C. et al. Autologous stem cell transplantation of treatment-resistant systemic vasculitis-a single center experience and review of the literature. Clin Nephrol 2005;64:485-9. Schlieben D.J., Korbet S.M., Kimura R.E. et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005;45:758-61. Xiao H., Heeringa P., Hu P. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-63. Bolton W.K., Innes D., Sturgill B.C., Kaiser D.L. T cells and macrophages in rapidly progressive glomerulonephritis: Clinicopathological correlates. Kidney Int 1987;32:869-76. Csernok E., Trabandt A., Muller A. et al. Cytokine profiles in Wegener's granulomatosis: predominace of type 1 (Th1) in the granulomatous inflammation. Arthr Rheum 1999;42:742-50. Balding C.E.J., Howie A.J., Drake-Lee A.B., Savage C.O.S. Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. Clin Exp Immunol 2001;125:332-9. Komocsi A., Lamprecht P., Csernok E. et al. Peripheral blood and granuloma CD4+ CD28- T cells are a major source of interferon-а and tumor necrosis factor-а in Wegener's granulomatosis. Am J Pathol 2002;160:1717-24. Cunningham M.A., Huang X.R., Dowling J.P. et al. Effectors of cellmediated immunity are prominent in “pauci-immune” glomerulonephritis. J Am Soc Nephrol 1999;10:499-506. Lamprecht P., Moosig F., Csernok E. et al. CD28 negative T cells are enriched in the granulomatous lesions of the respiratory tract in Wegener's granulomatosis. Thorax 2001;56:751-7. Van der Woude F.J., van Es L.A., Daha M.R. The role of c-ANCA antigen in the pathogenesis of Wegener's granulomatosis. A hypothesis based on both humeral and cellular mechanisms. Neth J Med 1990;36:169-71. Brouwer E., Stegeman C., Muitema M. et al. T-cell reactivity to proteinase 3 and myeloperoxidase in patients withWegener's granulomatosis. Clin Exp Immunol 1994;98:448-53. King W.J., Brooks C.J., Holder R. et al. T lymphocyte responses to anti-neutrophil cytoplasmic antibody (ANCA) antigens are present in patients with ANCA associated systemic vasculitis and persist during disease remission. Clin Exp Immunol 1998;112:539-46. Popa E.R., Franssen C.F., Limburg P.C. et al. In vitro cytokine production and proliferation of T cells from patients with antiproteinase 3-and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthr Rheum 2002;46:1894-904. Brouwer E., Tervaert J.W., Horst G. et al. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol 1991;83:379-86. Schmitt W.H., Heesen C., Csernok E. et al. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Arthr Rheum 1992;35:1088-96. Wang G., Csernok E., Gross W.L. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997;102:517-23. Ludviksson B.J., Sneller M.C., Chua K.S. et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998;160:3602-9. Plunkett W., Gandhi V., Cheson B. et al. Cellular pharmacology, mechanisms of action and strategies for combination therapy. In: Cheson B., Keating M., Plunkett W. (eds). Nucleoside analogs in cancer therapy. New York: Marcel Dekker, 1997;1 —35. Frank D.A., Mahajan S., Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999;5:444-7. Meng H., Yang C., Ni W. et al. Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo. Eur J Haematol 2007;79:486-93.; https://rsp.mediar-press.net/rsp/article/view/1171Test

الإتاحة: https://doi.org/10.14412/1995-4484-2012-1277Test
https://doi.org/10.14412/1995-4484-2012-2Test
https://rsp.mediar-press.net/rsp/article/view/1171Test

المؤلفون: V. Vasilyev I., S. Sedyshev Kh., V. Gorodetskii R., S. Radenska-Lopovok G., E. Rodionova B., O. Logvinenko A., N. Probatova A., E. Varlamova Yu., A. Dmitriev A., В. Васильев И., С. Седышев Х., В. Городецкий Р., С. Раденска-Лоповок Г., Е. Родионова Б., О. Логвиненко А., Н. Пробатова А., Е. Варламова Ю., А. Дмитриев А.

المصدر: Rheumatology Science and Practice; Vol 49, No 5 (2011); 92-97 ; Научно-практическая ревматология; Vol 49, No 5 (2011); 92-97 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2011-3

وصف الملف: application/pdf

العلاقة: https://rsp.mediar-press.net/rsp/article/view/1639/1185Test; https://rsp.mediar-press.net/rsp/article/view/1639Test

الإتاحة: https://doi.org/10.14412/1995-4484-2011-1467Test
https://doi.org/10.14412/1995-4484-2011-3Test
https://rsp.mediar-press.net/rsp/article/view/1639Test

المؤلفون: Vadim Gorodetsky Romanovich, Н Пробатова А, O Logvinenko A, В Васильев И, M Ogorodnikova D, С Седышев Х, М Симонова В, Т Сафонова Н, M Varlamova Yu, L Mekheda V, N Malakhova V, Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 48, No 2 (2010); 103-106 ; Научно-практическая ревматология; Vol 48, No 2 (2010); 103-106 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2010-2

مصطلحات موضوعية: rheumatoid arthritis, Sjogren's syndrome, MALT lymphoma, multiple myeloma, ревматоидный артрит, синдромом Шегрена, MALT-лимфома, множественная миелома

وصف الملف: application/pdf

العلاقة: https://rsp.mediar-press.net/rsp/article/view/1631/1125Test; https://rsp.mediar-press.net/rsp/article/view/1631Test

الإتاحة: https://doi.org/10.14412/1995-4484-2010-1423Test
https://doi.org/10.14412/1995-4484-2010-2Test
https://rsp.mediar-press.net/rsp/article/view/1631Test

المؤلفون: V Vasil'ev I, V Gorodetskiy R, S Sedyshev Kh, N Probatova A, A Pavlovskaya I, M Varlamova Yu, S Pal'shina G, A Logunov L, O Logvinenko A, E Sokol V, E Nasonov L, V Vasilyev I, V Gorodetsky R, S Palshina G, O Logvinenko, С. Седышев Х., Н. Пробатова А., А. Павловская И., А. Логунов Л., О. Логвиненко А., Евгений Насонов Львович, В. Васильев И., В. Городецкий Р., С. Пальшина Г.

المصدر: Rheumatology Science and Practice; Vol 48, No 1 (2010); 81-87 ; Научно-практическая ревматология; Vol 48, No 1 (2010); 81-87 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2010-1

مصطلحات موضوعية: myeloma, vasculitis, immunoglobulins, cryoglobulins, sepsis, миелома, васкулит, иммуноглобулины, криоглобулины, сепсис

وصف الملف: application/pdf

العلاقة: https://rsp.mediar-press.net/rsp/article/view/1249/920Test; Wintrobe M.M., Buell M.V. Hyperproteinemia associated with multiple myeloma. With report of a case in wich an extraordinary hyperproteinemia was associated with trombosis of retinal veins and symptomas suggesting Raynauds disease. Bull Johns Hopkins Hosp 1933;52:156. Brouet J.-C., Clauvel J.-P., Danon F. et al. Biologic and clinical significance of cryoglobulins. Review. A report of 86 cases. Amer J Med 1974;57:775-87. Goveric P.D., Kassab H.J., Levo Y. et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Review. Amer J Med 1980;69:287-307. Константинова Н.А. Криоглобулины и патология. М., Медицина, 1999. Anfimova M.L., Lebedeva T.V., Vassiliev V.I. et al. Fibronectin, cryoglobulinemia and immune complexes of patients with Sjogren's syndrome. Rus J Immun 1996;1:30-4. Белинин Г.Ю., Васильев В.И., Ефремов Е.Е., Васильев С.А. Клиническая эффективность криоафереза у больных с криоглобулинемиями. Тромбоз, гемостаз и реология 2004;4:20,45-55. Braun G.S., Horster S., Wagner K.S. et al. Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects. Review. Postgrad Med J 2007;83:87-94. Васильев В.И., Ходарев Н.В., Мач Э.С. и др. Криоглобулинемия при болезни Шегрена. Тер. архив 1990;5:66-70. Васильев В.И., Пробатова Н.А., Варламова Е.Ю. и др. Прогностическое значение смешанной моноклональной криоглобулинемии при болезни Шeгрена. Тер. архив 2004;8:61-68. Мануйлова Л.С. Клинико-морфологические изменения сосудов при болезни Шегрена: Дис. … канд. мед. наук. М., 1992. Ferri C., Sebastiani M., Giuggiali D. et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74. Tedeschi F., Barate C., Minola E., Morra E. Cryoglobulinemia. Review. Blood Reviews 2007;21:183-200. Васильев В. И., Пробатова Н.В., Тупицин Н.Н. и др. Лимфопролиферативные заболевания при болезни Шёгрена. Онкогематология 2007;3:16-26. Вотякова О.Н., Демина Е.А. Множественная миелома. Клиническая онкогематология. Под ред. М.А. Волковой. М., Медицина, 2001; с. 423-49. Андреева Н.Е., Балакирева Т.В. Множественная миелома. Руководство по гематологии. Т. 2. Под ред. А.И. Воробьева. М., Ньюдиамед, 2003; с. 151-73. Naschitz J.E. Rheumatic syndromes: сlues to occult neoplasia. Curr Opin Rheumatol 2001;13:62-6. Vital E.M., Emery P. Rheumatological manifestations of malignant heamatological conditions. Topical Reviews. Reports on the rheumatic diseases, series 5. 2007;11:1-8. Логвиненко О.А., Васильев В.И. Ассоциация между болезнью Шёгрена и лимфомами. Науч.-практ. ревматол. 2006;3:67-76. Тrejo O., Ramos-Casals M., Lopez-Guillermo A. et al. Hematologic malignancies in patients with cryoglobulinemia association with autoimmune and chronic viral diseases. Semin Arthr Rheum 2003;33:19-28. Palshina S.G., Vasiliev V.I. Primary and secondary Sjogren's syndrome in patients with chronic hepatobiliary diseases. 10th International symposium on Sjogren's syndrome. Abstract book. 2009; 120. Логвиненко О.А., Васильев В.И., Ковригина А.М. и др. Ритуксимаб в лечении нодальной В-клеточной лимфомы маргинальной зоны, болезни Шёгрена и аутоиммунного гепатита. Науч.-практ. ревматол. 2008;5:64-71. Logvinenko O.A., Vasilyev V.I., Simonova M.V. et al. Prognostic significance of monoclonal immunoglobulins in primary Sjogren's syndrome. Ann Rheum Dis 2005; 111(Suppl.):307. Blade J., Kyle R.A. Monoclonal gammopathies of undertermined significance. Myeloma. Biology and management. Eds Malpas J.S., Bersagel D.E., Kyle R.A., Anderson K.S. Oxford medical publications, 1998; p. 514-41. Городецкий В.Р., Пробатова Н.А., Васильев В.И. и др. Первичная плазмоци-тома лимфатических узлов. Гематол. и трансфузиол. 2006;51:3-8. Cancer. Principles and practice of oncology. Vol.2. 5th ed. Eds De Vita V.T., Heliman S., Rosenberg S.A. Philadelphia, Lippincott-Raven Publishers, 1997. Munford R.S. Severe sepsis and septic shock: the role of gram-negative bacteremia. Annu Rev Pathol Mech Dis 2006;1:467-77. Treatment of Multiple Myeloma and Related Disorders. Eds Rajkumar S.V., Kyle R.A. Cambridge University Press, 2009; p. 1-195. Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В. и др. Бортезамид (Велкейд) в комбинации с дексаметазоном в лечении рефрактерных/рецидивирующих форм множественной миеломы. Результаты заключительного анализа. Клин. онкогематол. 2009;2:236-45. Dispenzieri A., Merlini G., Comenzo R.L. Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biol of Blood Marrow Transplant 2008;14:6-11.; https://rsp.mediar-press.net/rsp/article/view/1249Test

الإتاحة: https://doi.org/10.14412/1995-4484-2010-1410Test
https://doi.org/10.14412/1995-4484-2010-1Test
https://rsp.mediar-press.net/rsp/article/view/1249Test